<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Lat Am Enfermagem</journal-id><journal-id journal-id-type="iso-abbrev">Rev Lat Am Enfermagem</journal-id><journal-title-group><journal-title>Revista Latino-Americana de Enfermagem</journal-title></journal-title-group><issn pub-type="ppub">0104-1169</issn><issn pub-type="epub">1518-8345</issn><publisher><publisher-name>Escola de Enfermagem de Ribeir&#x000e3;o Preto / Universidade de S&#x000e3;o
Paulo</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25493671</article-id><article-id pub-id-type="pmc">4292677</article-id><article-id pub-id-type="doi">10.1590/0104-1169.3443.2478</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Chlorhexidine and gauze and tape dressings for central venous catheters:
a randomized clinical trial<xref ref-type="fn" rid="fn01">
<sup>1</sup>
</xref>
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pedrolo</surname><given-names>Edivane</given-names></name><xref ref-type="aff" rid="aff1">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Danski</surname><given-names>Mitzy Tannia Reichembach</given-names></name><xref ref-type="aff" rid="aff2">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vayego</surname><given-names>Stela Adami</given-names></name><xref ref-type="aff" rid="aff2">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1"><label>2</label>Doctoral student, Universidade Federal do Paran&#x000e1;, Curitiba, PR, Brazil.
Professor, Instituto Federal do Paran&#x000e1;, Curitiba, PR, <country>Brazil</country></aff><aff id="aff2"><label>3</label>PhD, Adjunct Professor, Universidade Federal do Paran&#x000e1;, Curitiba, PR,
<country>Brazil</country></aff><author-notes><corresp id="c01"><bold>Corresponding Author:</bold> Edivane Pedrolo Av. Jo&#x000e3;o Negr&#x000e3;o, 1285 Bairro:
Rebou&#x000e7;as CEP: 80230-150, Curitiba, PR, Brasil E-mail:
<email>edivanepedrolo@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Sep-Oct</season><year>2014</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2014</year></pub-date><volume>22</volume><issue>5</issue><fpage>764</fpage><lpage>771</lpage><history><date date-type="received"><day>19</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>OBJECTIVE:</title><p> to assess the effectiveness of the chlorhexidine antimicrobial dressing in
comparison to the gauze and tape dressing in the use of central venous catheters.
</p></sec><sec><title>METHOD:</title><p> a randomized clinical trial was conducted in the intensive care and adult semi
intensive care units of a university hospital in the south of Brazil. The subjects
were patients using short-term central venous catheters, randomly assigned to the
intervention (chlorhexidine antimicrobial dressing) or control (gauze and micro
porous tape) groups. </p></sec><sec><title>RESULTS:</title><p> a total of 85 patients were included: 43 in the intervention group and 42 in the
control group. No statistically significant differences were found between
dressings in regard to the occurrence of: primary bloodstream infections (p-value
= 0.5170); local reactions to the dressing (p-value = 0.3774); and dressing
fixation (p-value = 0.2739). </p></sec><sec><title>CONCLUSION:</title><p> both technologies are effective in covering central venous catheters in regard to
the investigated variables and can be used for this purpose. Registry ECR:
RBR-7b5ycz.</p></sec></abstract><kwd-group><kwd>Clinical Trial</kwd><kwd>Chlorhexidine</kwd><kwd>Catheterization, Central Venous</kwd><kwd>Technology</kwd><kwd>Nursing</kwd><kwd>Bandages</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="15"/><page-count count="8"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The Central Venous Catheter (CVC) is a device largely used by patients in critical
health conditions. Its use, however, may entail many complications, among which is
Primary Bloodstream Infection (PBSI), which is the most common bloodstream infection in
patients with a CVC for more than 48 hours and that is not related to another
site<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup>.</p><p>A concern to promote measures that reduce PBSI is justified given the high rates of
associated morbidity and mortality. A patient affected by this complication will remain
hospitalized for another seven to 21 days, with a consequent increase in hospital costs
from U$3,700 to U$29,000 and in a risk of death; attributable mortality for this
infection is 18%<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup>.</p><p>In Brazil, it is estimated that 60% of infections are catheter-related PBSI, especially
short-term catheters<sup>(</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup>. Considering the relevance of this figure, the Brazilian Health
Surveillance Agency (ANVISA) has made efforts to prevent this complication. Among the
measures adopted is the goal to reduce PBSI rates by 30% in three years<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup>. Various facilities in the international context have reported the adoption
of severe measures to reduce PBSI rates to zero. Given the impact of this complication
for patients and healthcare services, a continuous search for effective prevention is
justified<sup>(</sup>
<xref rid="B05" ref-type="bibr">5</xref>
<sup>)</sup>.</p><p>Despite the large number of PBSI risk factors, these are minimized with the adoption of
interventions upon catheter insertion and maintenance such as: implementation of bundle
care (hand hygiene, maximum barrier precautions upon insertion, chlorhexidine skin
antisepsis, optimal catheter site, and prompt removal)<sup>(</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>; maintaining the output opening, occluded with sterile dressing; among
other interventions<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">3</xref>
<sup>)</sup>.</p><p>In regard to sterile occlusive dressings, there are different technologies on the
market, such as gauze and tape, transparent polyurethane film dressing, and
chlorhexidine antimicrobial dressing. These vary in terms of durability, ease of
application, skin reaction, and ability to prevent infections. Gauze and tape dressings
and transparent polyurethane film have been widely investigated recently and meta
analysis addressing this topic reports that the latter leads to four times as many
infections<sup>(</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup>.</p><p>Knowledge is still incipient in regard to the chlorhexidine antimicrobial dressing.
There are few studies in the international literature, which hinders the incorporation
of this new technology into nursing practice. Evidence currently available does not
show, with any statistical significance, how effective this technology is in reducing
PBSI rates. Hence, both the Center for Disease Control and Prevention and ANVISA
recommend the use of this technology only in units where high PBSI rates remain even
after adopting all measures recommended by the literature. Its indication for other
patients remains elusive<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup>.</p><p>Therefore, this study's aim was to assess the effectiveness of chlorhexidine
antimicrobial dressings in comparison to gauze and tape dressings for the following
outcomes: prevention of primary bloodstream infections, local reactions, and fixation of
dressings.</p></sec><sec sec-type="methods"><title>Method</title><p>The study was approved by the Institutional Review Board under the record CEP/SD
1145.070.11.06 and CAAE 0067.0.091.208-11, and registered in the Brazilian Clinical
Trials Registry under No. ECR: RBR-7b5ycz. This randomized clinical trial<sup>(</sup>
<xref rid="B08" ref-type="bibr">8</xref>
<sup>)</sup> was conducted in the Intensive Care Unit (ICU) and Adult Semi Intensive
Care Unit (ASICU) of a university hospital in the South of Brazil from October 2011 to
May 2012. The study's participants were severe clinical and surgical patients. </p><p>A pilot test with eight patients was conducted from October 18<sup>th</sup> to November
2<sup>nd</sup> to estimate the proportion of CVC-related infections or local
reactions. The patients enrolled in this test were not included in the final study. The
inclusion of patients in the study followed the scheme shown in <xref ref-type="fig" rid="f01">Figure 1</xref>. We employed a randomized technique in blocks of six
patients with a sequence of random numbers generated by Excel<sup>(r)(8)</sup>.</p><p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>- Flowchart for the inclusion of participants in the study</title></caption><graphic xlink:href="0104-1169-rlae-22-05-00764-gf01"/></fig>
</p><p>After randomization, the dressings were changed for the first time and the technology to
which the patient was assigned was applied. At this point, we collected the
socio-demographic and clinical variables, along with catheter data using an instrument
defined in the pilot test. Afterwards, the participants were assessed for the collection
of the outcome variables as described below.</p><p>The outcome variables included: PBSI, fixation of dressing to skin, and local reaction
to dressing. In this study, PBSI was the presence of at least one of the following signs
and symptoms: fever (&#x0003e;38&#x000b0;); shivering; urine output&#x0003c;20ml/h; systolic blood
pressure &#x02264; 90mmHg; no apparent infection in another site; and medical prescription of
antimicrobial therapy for sepsis<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup>. </p><p>Note that the patients using antimicrobial agents prior to the catheter placement were
included in the study provided they did not present clinical diagnosis of sepsis; the
PBSI criteria established in the literature did not indicate the need to exclude these
patients<sup>(</sup>
<xref rid="B04" ref-type="bibr">4</xref>
<sup>)</sup>.</p><p>The following information, collected daily, was standardized to establish the infection
variable: temperature&#x0003e;38&#x000ba;C, systolic blood pressure&#x0003c;90 mmHg, oliguria&#x0003c;20ml/h,
tenderness, pain or swelling on palpation, hyperemia, cyanosis or discharge at the
catheter opening. In the event of a clinical suspicion of PBSI, a blood culture or a
culture of the catheter tip was collected according to medical recommendations, a
routine procedure of the service where the study was conducted. The catheter tip was
collected only for patients with sepsis for whom it was not possible to define the
infectious focus by blood culture only.</p><p>For the local reaction variable, we observed signs and symptoms. Local reaction was
considered to be present when the patient presented at least one of the following:
maceration, hyperemia, desquamation or itching in the region where there was contact
between skin and dressing. For the fixation variable, we assessed whether the edges were
detached, regardless of whether the integrity of the dressing was compromised. Good
fixation was considered to have occurred when the dressing remained intact in more than
75% of the observations. The analysis of variables, local reaction and fixation was
performed always at the same time by a staff member previously trained for data
collection and, if there was doubt, a second evaluator would assess the variables, as
well.</p><p>The chlorhexidine antimicrobial dressing was changed every seven days and gauze and tape
every 48 hours<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup>, or less whenever the dressing edges detached and compromised the dressing
integrity or discharge accumulated in the catheter opening<sup>(</sup>
<xref rid="B02" ref-type="bibr">2</xref>
<sup>)</sup>. For the catheter puncture, we used the standardized technique adopted by
the unit that is based on the care bundle recommended by international clinical
guidelines<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">6</xref>
<sup>)</sup>. A qualified staff member exclusively performed the dressings using a
standardized technique. Patients were monitored up to the end point, which comprised
transference to another hospital facility, puncture of a second catheter, or its
removal. Patients discharged from the ICU or ASICU to a hospitalization ward were also
monitored up to the aforementioned end points.</p><p>A proportion of PBSI of 60% was considered for the control group for the sampling
computation based on the pilot test. A sample of 42 patients was estimated for each
group (power of 0.80 (1 - &#x003b2; = 0.80)), with a minimum difference of 30% between
treatments and levels of significance of 0.05 (&#x003b1; = 0.05). Data were analyzed using
descriptive statistics associated with Fisher's exact test and Williams' G-test
(qualitative variables) and the Mann-Whitney U-test (quantitative variables),
considering a level of significance of 5%.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 43 patients were included in the intervention group (chlorhexidine
antimicrobial dressing - CHD) and 42 in the control group (gauze and tape dressing).
There was no follow-up loss of the patients included in the study. Socio-demographic and
clinical data are presented in <xref ref-type="table" rid="t01">Table 1</xref> and
catheter-related data are presented in <xref ref-type="table" rid="t02">Table 2</xref>.
The average age of the participants in the CHD group was 55.1 (SD=16.3) years old and
that of the participants in the gauze and tape group was 60.2 (SD=18.9) years old, with
no statistical difference (p = 0.0929). All the analyzed catheters were made of
polyurethane.</p><p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>- Distribution of frequency (n) and percentage (%) of socio-demographic and
clinical variables of patients in the intervention (chlorhexidine antimicrobial
dressing) and control (gauze and tape) groups. Curitiba, PR, Brazil,
2012</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 100%"><thead><tr><th align="center" colspan="2" rowspan="2">Variable</th><th align="center" colspan="2" rowspan="1">Chlorhexidine Intervention group
(n=43)</th><th align="center" rowspan="2" colspan="1">
</th><th align="center" colspan="2" rowspan="1">Control group<break/> dressing
(n=42)</th><th align="center" rowspan="2" colspan="1">p-value</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td colspan="2" rowspan="1"> Sex</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.5379*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Female</td><td align="center" rowspan="1" colspan="1"> 19</td><td align="center" rowspan="1" colspan="1"> 44.2</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 18</td><td align="center" rowspan="1" colspan="1"> 42.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Male</td><td align="center" rowspan="1" colspan="1"> 24</td><td align="center" rowspan="1" colspan="1"> 55.8</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 24</td><td align="center" rowspan="1" colspan="1"> 57.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Ethnicity </td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.1663*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Caucasian</td><td align="center" rowspan="1" colspan="1"> 36</td><td align="center" rowspan="1" colspan="1"> 83.7</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 39</td><td align="center" rowspan="1" colspan="1"> 92.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> African-descendant</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1"> 16.3</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1"> 7.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Primary focus of pathology</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.2669<sup>&#x02020;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Digestive system</td><td align="center" rowspan="1" colspan="1"> 18</td><td align="center" rowspan="1" colspan="1"> 41.9</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1"> 21.4</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Nervous system</td><td align="center" rowspan="1" colspan="1"> 10</td><td align="center" rowspan="1" colspan="1"> 23.2</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 11</td><td align="center" rowspan="1" colspan="1"> 26.2</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Malignant neoplasia</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1"> 16.3</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1"> 16.7</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Circulatory system</td><td align="center" rowspan="1" colspan="1"> 2</td><td align="center" rowspan="1" colspan="1"> 4.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Other</td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1"> 14.0</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 10</td><td align="center" rowspan="1" colspan="1"> 23.8</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Comorbidities</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.2683<sup>&#x02020;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> One</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 12</td><td align="center" rowspan="1" colspan="1"> 28.6</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Two </td><td align="center" rowspan="1" colspan="1"> 13</td><td align="center" rowspan="1" colspan="1"> 30.2</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1"> 19.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Three</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1"> 9.5</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Four or more</td><td align="center" rowspan="1" colspan="1"> 2</td><td align="center" rowspan="1" colspan="1"> 4.7</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1"> 9.5</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> No comorbidities</td><td align="center" rowspan="1" colspan="1"> 18</td><td align="center" rowspan="1" colspan="1"> 41.9</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 14</td><td align="center" rowspan="1" colspan="1"> 33.3</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Hospitalization unit</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.2298*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Intensive Care Unit</td><td align="center" rowspan="1" colspan="1"> 40</td><td align="center" rowspan="1" colspan="1"> 93.0</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 36</td><td align="center" rowspan="1" colspan="1"> 85.7</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Semi-intensive care unit</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1"> 7.0</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1"> 14.3</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Discharge or death</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.3784*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Discharge</td><td align="center" rowspan="1" colspan="1"> 27</td><td align="center" rowspan="1" colspan="1"> 62.8</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 24</td><td align="center" rowspan="1" colspan="1"> 57.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Death</td><td align="center" rowspan="1" colspan="1"> 16</td><td align="center" rowspan="1" colspan="1"> 37.2</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 18</td><td align="center" rowspan="1" colspan="1"> 42.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Antimicrobial before puncture</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.5152<sup>&#x02020;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> One antimicrobial</td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1"> 14.0</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 10</td><td align="center" rowspan="1" colspan="1"> 23.8</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Two antimicrobial</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1"> 20.9</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1"> 19.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Three or more antimicrobial</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1"> 7.0</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> No</td><td align="center" rowspan="1" colspan="1"> 25</td><td align="center" rowspan="1" colspan="1"> 58.1</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 19</td><td align="center" rowspan="1" colspan="1"> 45.2</td><td align="center" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn id="t01TFN01"><label>*</label><p> Fisher's exact test</p></fn><fn id="t01TFN02"><label>&#x02020;</label><p> G-test</p></fn></table-wrap-foot></table-wrap>
</p><p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><title>- Distribution of frequency (n) and percentage (%) of catheter-related
variables in patients within the intervention (chlorhexidine intervention
group) and control (gauze and tape dressing) groups. Curitiba. PR, Brazil,
2012</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 100%"><thead><tr><th align="center" colspan="2" rowspan="2">Variable</th><th align="center" colspan="2" rowspan="1">Chlorhexidine Intervention group
(n=43)</th><th align="center" rowspan="1" colspan="1">
</th><th align="center" colspan="2" rowspan="1">Control group<break/> dressing
(n=42)</th><th align="center" rowspan="2" colspan="1">p-value</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td colspan="2" rowspan="1"> Indication</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.8053*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Administration of vasoactive
drugs</td><td align="center" rowspan="1" colspan="1"> 38</td><td align="center" rowspan="1" colspan="1"> 88.4</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 37</td><td align="center" rowspan="1" colspan="1"> 88.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Monitoring</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1"> 9.3</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1"> 7.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Total parenteral nutrition</td><td align="center" rowspan="1" colspan="1"> 1</td><td align="center" rowspan="1" colspan="1"> 2.3</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 2</td><td align="center" rowspan="1" colspan="1"> 4.8</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Unit where puncture was performed</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.9654*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Clinical</td><td align="center" rowspan="1" colspan="1"> 1</td><td align="center" rowspan="1" colspan="1"> 2.3</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 1</td><td align="center" rowspan="1" colspan="1"> 2.4</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Surgical center</td><td align="center" rowspan="1" colspan="1"> 17</td><td align="center" rowspan="1" colspan="1"> 39.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 17</td><td align="center" rowspan="1" colspan="1"> 40.5</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Semi-intensive care unit</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1"> 16.7</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Intensive care unit</td><td align="center" rowspan="1" colspan="1"> 16</td><td align="center" rowspan="1" colspan="1"> 37.2</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 13</td><td align="center" rowspan="1" colspan="1"> 30.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Emergency room</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1"> 9.3</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1"> 9.5</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Number of lumen catheter</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.6156<sup>&#x02020;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> One </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Two</td><td align="center" rowspan="1" colspan="1"> 38</td><td align="center" rowspan="1" colspan="1"> 88.4</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 37</td><td align="center" rowspan="1" colspan="1"> 88.1</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Anatomical site of catheter insertion</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.2948<sup>&#x02020;</sup>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Subclavian</td><td align="center" rowspan="1" colspan="1"> 31</td><td align="center" rowspan="1" colspan="1"> 72.1</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 27</td><td align="center" rowspan="1" colspan="1"> 64.3</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Jugular</td><td align="center" rowspan="1" colspan="1"> 12</td><td align="center" rowspan="1" colspan="1"> 27.9</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 15</td><td align="center" rowspan="1" colspan="1"> 35.7</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" rowspan="1"> Reason follow-up ceased</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.9678*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Catheter removal</td><td align="center" rowspan="1" colspan="1"> 25</td><td align="center" rowspan="1" colspan="1"> 58.2</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 23</td><td align="center" rowspan="1" colspan="1"> 54.8</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> Death</td><td align="center" rowspan="1" colspan="1"> 11</td><td align="center" rowspan="1" colspan="1"> 25.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 11</td><td align="center" rowspan="1" colspan="1"> 26.2</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Placement of a second
catheter</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.9</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> &#x000a0;Non-infectious diseases</td><td align="center" rowspan="1" colspan="1"> 2</td><td align="center" rowspan="1" colspan="1"> 4.6</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1"> 7.1</td><td align="center" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn id="t02TFN01"><label>*</label><p>G-test</p></fn><fn id="t02TFN02"><label>&#x02020;</label><p>Fisher's exact test</p></fn></table-wrap-foot></table-wrap>
</p><p>The average time of hospitalization was similar between groups: 9.7 (SD=13.7) days for
the CHD group and 9.5 (SD=9.1) for the gauze and tape group (p = 0.1418). Duration of
catheter placement was 4.9 (SD=2.5) days for the CHD group and 5 (SD=2.7) days for the
gauze and tape group, with no statistical difference (p = 0.1418).</p><p>No significant differences were found between the dressings in regard to the occurrence
of PBSI (p-value = 0.5170). Laboratorial confirmation of PBSI was obtained through blood
cultures in 16 patients from the chlorhexidine group (37.21%) and in 17 patients from
the gauze and tape group (40.48%), and with analysis of the catheter tip in three
patients from the chlorhexidine (6.98%) group, for whom establishment of infectious
focus was not possible through blood culture only. Four clinical PBSI and one with
laboratorial confirmation, in which the <italic>Candida krusei</italic> microorganism
was isolated, were observed in the gauze and tape group. All the cases in the CHD group
were clinical (<xref ref-type="table" rid="t03">Table 3</xref>).</p><p>
<table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><title>- Variables related to primary bloodstream infections, local reactions and
fixation of dressing in patients from the intervention (chlorhexidine
antimicrobial dressing) and control (gauze and tape) groups. Curitiba, PR,
Brazil, 2012</title></caption><table frame="hsides" rules="groups" style="border-top: 1px solid black; border-bottom: 1px solid black; width: 100%"><thead><tr><th align="center" colspan="2" rowspan="2">Variable</th><th align="center" colspan="2" rowspan="1">Chlorhexidine Intervention group
(n=43)</th><th align="center" rowspan="2" colspan="1">
</th><th align="center" colspan="2" rowspan="1">Control group dressing
(n=42)</th><th align="center" rowspan="2" colspan="1">p-value</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td colspan="2" rowspan="1"> Primary bloodstream infection</td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1"> 13.95</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1"> 11.90</td><td align="center" rowspan="1" colspan="1"> 0.5170*</td></tr><tr><td colspan="2" rowspan="1"> Local reaction to dressing</td><td align="center" rowspan="1" colspan="1"> 17</td><td align="center" rowspan="1" colspan="1"> 39.53</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 19</td><td align="center" rowspan="1" colspan="1"> 45.24</td><td align="center" rowspan="1" colspan="1"> 0.3774*</td></tr><tr><td colspan="2" rowspan="1"> Signs and symptoms of local reaction</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Hyperemia</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1"> 20.93</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1"> 21.43</td><td align="center" rowspan="1" colspan="1"> 0.5824*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Maceration</td><td align="center" rowspan="1" colspan="1"> 10</td><td align="center" rowspan="1" colspan="1"> 23.26</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 12</td><td align="center" rowspan="1" colspan="1"> 28.57</td><td align="center" rowspan="1" colspan="1"> 0.3777*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Desquamation </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1"> 9.30</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 2</td><td align="center" rowspan="1" colspan="1"> 4.76</td><td align="center" rowspan="1" colspan="1"> 0.3493*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Itching</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1"> 6.98</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1"> 7.14</td><td align="center" rowspan="1" colspan="1"> 0.6507*</td></tr><tr><td colspan="2" rowspan="1"> Fixation</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 0.2739*</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Good</td><td align="center" rowspan="1" colspan="1"> 36</td><td align="center" rowspan="1" colspan="1"> 83.72</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 38</td><td align="center" rowspan="1" colspan="1"> 90.48</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="center" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1"> Poor</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1"> 16.28</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1"> 9.52</td><td align="center" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn id="t03TFN01"><label>*</label><p>Fisher's exact test</p></fn></table-wrap-foot></table-wrap>
</p><p>Association between signs and symptoms at the catheter opening and the occurrence of
PBSI was tested regardless of the type of dressing used and no statistical significance
was found between PBSI and the variables: hyperemia at the opening (p-value = 0.2042),
cyanosis at the opening (p-value= 0.6181), serous discharge (p-value = 0.4255),
serosanguineous discharge (p-value = 0.5881), sanguineous discharge (p-value = 0.1048),
purulent discharge (p-value = 0.3420) swelling upon palpation (p-value = 0.2993), and
pain to palpation (p-value = 0.2695).</p><p>Both dressings presented good fixation and the participants presented a high incidence
of local reaction (39.53% - chlorhexidine and 45.24% - gauze) with no statistically
significant differences between groups. Most cases of local reaction were characterized
by skin hyperemia and maceration. Note that there was one case of a severe reaction to
the dressing in the intervention group and for this reason that participant was excluded
from the study (<xref ref-type="table" rid="t03">Table 3</xref>).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Catheter-related infection is a complication that greatly influences the morbidity and
mortality of patients using CVCs, a fact that justifies unceasing efforts to promote
preventive evidence-based interventions. The technologies addressed in this study are
safe options for occluding catheter openings due to the low incidence of PBSI in both
groups (13.95% - CHD; 11.90% - gauze). No significant differences were found between the
dressings in regard to the occurrence of PBSI (p-value = 0.5170). The incidence of PBSI,
however, can be even lower, as shown in a cohort study conducted in seven ICUs that
reported an infection rate 6.4%<sup>(</sup>
<xref rid="B09" ref-type="bibr">9</xref>
<sup>)</sup>.</p><p>One meta analysis and two clinical trials<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>-</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup> were found in an extensive search of the literature<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>)</sup>. These studies assessed the ability of chlorhexidine dressings to reduce
colonization rates and PBSI. Nonetheless, all studies used transparent polyurethane
dressings in the control group. This is the first Brazilian study addressing this new
technology that also employs gauze and tape as the control group. Note that this is a
safe choice, since the meta analysis included six clinical trials comparing gauze and
tape with transparent polyurethane and revealed no differences between these
technologies in regard to the incidence of catheter-related infectious
complications<sup>(</sup>
<xref rid="B07" ref-type="bibr">7</xref>
<sup>)</sup>.</p><p>A meta analysis that included eight randomized clinical trials assessing
chlorhexidine-impregnated dressing showed that this technology has a tendency to reduce
PBSI, though with no statistical evidence<sup>(</sup>
<xref rid="B10" ref-type="bibr">10</xref>
<sup>)</sup>. Two new clinical trials were published in 2009 addressing this topic and
both showed significant decrease in PBSI among patients using chlorhexidine
dressings<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>-</sup>
<xref rid="B12" ref-type="bibr">12</xref>
<sup>)</sup>. The studies, however, used a sponge impregnated with chlorhexidine, which
needs to be covered with transparent polyurethane dressing. In this study, the
chlorhexidine dressing used consists of a transparent film, the adhesive of which
contains chlorhexidine gluconate gel at 2%.</p><p>The reduced indexes of PBSI in ICU are a result of the massive adoption of preventive
measures on the part of the medical and nursing staffs. Additionally, constant
monitoring of patients is an important factor that culminates in the removal of the
device and early identification of complications. The adoption of these measures in the
studied units may have limited the results found, especially in regard to the early
removal of devices.</p><p>Note that the absence of statistically significant differences in the effectiveness of
chlorhexidine and gauze and tape dressings in the prevention of PBSI may have been
influenced by the fact that only the first CVC of each patient was included in the
analysis, since the more frequently patients are exposed to CVC, the higher the risk of
complications. Another important factor is related to the short duration of catheter
placement, as periods longer that five days are associated with a higher risk of
infection.</p><p>The PBSI-related microorganisms most frequently found are
<italic>Staphylococcus</italic> coagulase-negative, <italic>Staphylococcus aureus,
Enterococcus </italic>and<italic> Candida</italic> spp.<sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup>. The only case of infection confirmed by a laboratory was associated with
the <italic>Candida krusei </italic>microorganism.</p><p>Hyperemia (20.93% - CHD; 23.81% - gauze) in the catheter opening was the sign most
frequently observed in this study, while purulent discharge was the least observed
(4.65% - CHD; 2.38% - gauze), though none presented significant association with the
occurrence of PBSI. One study conducted with 37 patients who acquired PBSI in a
university hospital found the following to be the two most frequent signs: purulent
discharge (27%) and hyperemia in the catheter opening (18.9%)<sup>(</sup>
<xref rid="B13" ref-type="bibr">13</xref>
<sup>)</sup>. International clinical guidelines recommend daily inspection and palpation
of the catheter site to check for signs of inflammation <sup>(</sup>
<xref rid="B01" ref-type="bibr">1</xref>
<sup>)</sup>. Data resulting from palpation, however, such as edema (p-value = 0.2993)
and pain (p-value = 0.2695) did not present a significant relationship with the PBSI
outcome.</p><p>The dressings analyzed in this study were associated with local reactions (CHD - 39.53%;
gauze - 45.24%), however, no statistical significant difference was found between the
groups. According to the data found, one randomized clinical trial conducted with 21 ICU
inpatients also reported a high rate of gauze and tape-related local reaction
(60%)<sup>(</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>)</sup>. The clinical signs more frequently observed for gauze and tape dressings
were skin maceration (28.57%) and hyperemia (21.43%). Even though the micro-porous tape
is hypoallergenic, the signs observed were concentrated in the region in which skin was
in contact with the tape and not in the region of direct contact between the gauze and
the patient's skin.</p><p>In regard to the chlorhexidine dressing, the part composed of transparent film is
hypoallergenic, however chlorhexidine is associated with hypersensitivity. The clinical
signs most frequently observed in patients using this type of dressing were skin
maceration (28.57%) and hyperemia (21.43%), which were concentrated in the entire region
of contact between the dressing and skin. This variable was assessed because a local
reaction may compromise the integrity of peri-catheter skin and increase the likelihood
of greater colonization in the region.</p><p>There was one case of a severe reaction to CHD, a fact that caused discontinuing the
patient in the study. We note, however, the low incidence of severe reactions to the
dressing, a fact that would impede its widespread use and reaffirms the view that this
dressing should be prescribed only for patients who do not present known
hypersensitivity to chlorhexidine antisepsis. There is one study corroborating these
findings, as it reports that chlorhexidine is well-tolerated by patients<sup>
(15)</sup>.</p><p>The technique used to apply dressings to cover CVCs is sterile with the use of material
free of microorganisms that may cause infection due to continued solution in the region
of the catheter opening area. In order to maintain low bacterial load in this region,
the dressing must strongly adhere to skin to prevent the catheter opening from coming
into contact with air. Note that both studied groups presented good fixation (83.72% -
CHD; 90.48% - gauze); no statistical differences were found in regard to dressing
fixation (0.2739).</p><p>Two studies assessed the variable for the fixation of dressing, one of which assessed
gauze and tape fixation and the other assessed the fixation of the chlorhexidine
dressing. The randomized clinical trial assessing chlorhexidine dressing included 1,636
patients. It reports that approximately 40% of the dressing changes were detached from
the skin, which led to early changing of the dressing<sup>(</sup>
<xref rid="B11" ref-type="bibr">11</xref>
<sup>)</sup>. The randomized clinical trial assessing gauze and tape dressing shows that
50% of the dressings used in the analyzed catheters presented poor fixation and required
early changing<sup>(</sup>
<xref rid="B14" ref-type="bibr">14</xref>
<sup>)</sup>. In this study, the rates of poor fixation found for both the gauze and
tape and chlorhexidine dressings were lower than that reported in the literature. Note
that the good fixation of dressings found in this study is a factor relevant for the
maintenance of occluded dressings, which favors the reduced colonization of
peri-catheter skin.</p><p>Limitations of this study include the fact that the severity of the patients' clinical
conditions was not related to the investigated outcomes, nor were the nutritional states
of patients. These are factors that directly impact the susceptibility of patients to
infectious complications and likely factors linked to the PBSI outcome. Additionally,
patients using antimicrobial agents may have masked the occurrence of sepsis with the
action of medications, a fact that may have interfered in the studied outcome and,
therefore, is a limitation of this study.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The objective was to assess the effectiveness of the chlorhexidine antimicrobial
dressing in comparison to the gauze and tape dressing for the outcomes: prevention of
primary bloodstream infections, local reactions, and the fixation of dressings.</p><p>This study shows that, in a unit that adopts catheter bundle care, the chlorhexidine
antimicrobial dressing is not effective in reducing PBSI when compared to the gauze and
tape dressing. In regard to the occurrence of local reactions and the fixation of
dressings, no statistically significant differences were found between groups. A high
rate of local reaction was observed in both groups, as well as the occurrence of a
severe skin reaction in the case of one patient using the chlorhexidine dressing.</p><p>Both the technologies addressed in this study are effective in covering CVCs in regard
to the assessed outcomes and can be employed for this purpose. We recommend further
research to consolidate scientific evidence for the use of chlorhexidine dressing in the
prevention of primary bloodstream infections in critical patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank 3M Brazil for providing the dressings used in the clinical trial without
interfering in the study or its results.</p></ack><fn-group><fn id="fn01" fn-type="supported-by"><label>1</label><p> Paper extracted from master's thesis "Chlorhexidine dressing for central venous
catheters: a randomized clinical trial" presented to Universidade Federal do Paran&#x000e1;,
Curitiba, PR, Brazil</p></fn></fn-group><ref-list><title>References</title><ref id="B01"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>O'Grady</surname><given-names>NP</given-names></name><name><surname>Alexander</surname><given-names>M</given-names></name><name><surname>Burns</surname><given-names>LA</given-names></name><name><surname>Dellinger</surname><given-names>EP</given-names></name><name><surname>Garland</surname><given-names>J</given-names></name><name><surname>Heard</surname><given-names>SO</given-names></name></person-group><source>Guidelines for the prevention of intravascular catheter-related
infections</source><publisher-loc>Washington</publisher-loc><publisher-name>CDC</publisher-name><year>2011</year><ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/content/52/9/e162.long">http://cid.oxfordjournals.org/content/52/9/e162.long</ext-link></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Springhouse</collab></person-group><source xml:lang="pt">As melhores pr&#x000e1;ticas de enfermagem: procedimentos baseados em
evid&#x000ea;ncias</source><edition>2&#x000aa; ed</edition><publisher-loc>Porto Alegre</publisher-loc><publisher-name>Artmed</publisher-name><year>2010</year><size units="pages">640 p</size></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Ag&#x000ea;ncia Nacional de Vigil&#x000e2;ncia Sanit&#x000e1;ria (BR)</collab></person-group><source xml:lang="pt">Indicadores nacionais de infec&#x000e7;&#x000f5;es relacionadas &#x000e0; assist&#x000ea;ncia a
sa&#x000fa;de - corrente sangu&#x000ed;nea</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>ANVISA</publisher-name><year>2010</year><ext-link ext-link-type="uri" xlink:href="http://portal.anvisa.gov.br/wps/wcm/connect/1ff4120047457e9b8a6ede3fbc4c6735/INDICADORES+NACIONAIS+DE+INFEC%C3%87%C3%83O+-+Setembro+2010+-+NOVO.pdf?MOD=AJPERES">http://portal.anvisa.gov.br/wps/wcm/connect/1ff4120047457e9b8a6ede3fbc4c6735/INDICADORES+NACIONAIS+DE+INFEC%C3%87%C3%83O+-+Setembro+2010+-+NOVO.pdf?MOD=AJPERES</ext-link></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Ag&#x000ea;ncia Nacional de Vigil&#x000e2;ncia Sanit&#x000e1;ria (BR)</collab></person-group><source xml:lang="pt">Orienta&#x000e7;&#x000f5;es para preven&#x000e7;&#x000e3;o de infec&#x000e7;&#x000e3;o prim&#x000e1;ria de corrente
sangu&#x000ed;nea</source><publisher-loc>Bras&#x000ed;lia</publisher-loc><publisher-name>ANVISA</publisher-name><year>2010</year><ext-link ext-link-type="uri" xlink:href="http://portal.anvisa.gov.br/wps/wcm/connect/ef02c3004a04c83ca0fda9aa19e2217c/manual+Final+preven%C3%A7%C3%A3o+de+infec%C3%A7%C3%A3o+da+corrente.pdf?MOD=AJPERES">http://portal.anvisa.gov.br/wps/wcm/connect/ef02c3004a04c83ca0fda9aa19e2217c/manual+Final+preven%C3%A7%C3%A3o+de+infec%C3%A7%C3%A3o+da+corrente.pdf?MOD=AJPERES</ext-link></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Southworth</surname><given-names>SL</given-names></name><name><surname>Henman</surname><given-names>LJ</given-names></name><name><surname>Kinder</surname><given-names>LA</given-names></name><name><surname>Sell</surname><given-names>JL</given-names></name></person-group><article-title>The journey to zero central catheter&#x02212;associated
bloodstream infections: culture change in an intensive care unit</article-title><source>Crit Care Nurse.</source><year>2012</year><volume>32</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">22467612</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osorio</surname><given-names>J</given-names></name><name><surname>&#x000c1;lvarez</surname><given-names>D</given-names></name><name><surname>Pacheco</surname><given-names>R</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>CA</given-names></name><name><surname>Lozano</surname><given-names>A</given-names></name></person-group><article-title>Implementation of an insertion bundle for preventing
central line-associated bloodstream infections in an Intensive Care Unit in
Colombia</article-title><source>Rev Chil Infectol.</source><month>10</month><year>2013</year><volume>30</volume><issue>5</issue><fpage>465</fpage><lpage>473</lpage></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>J</given-names></name><name><surname>Gillies</surname><given-names>D</given-names></name><name><surname>O'Riordan</surname><given-names>E</given-names></name><name><surname>Sherriff</surname><given-names>KL</given-names></name><name><surname>Rickard</surname><given-names>CM</given-names></name></person-group><chapter-title>Gauze and tape and transparent polyurethane dressings
for central venous catheters (Cochrane Review)</chapter-title><person-group person-group-type="author"><collab>The Cochrane Library</collab></person-group><year>2011</year><ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003827.pub2/abstract">http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003827.pub2/abstract</ext-link></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hulley</surname><given-names>SB</given-names></name><name><surname>Cummins</surname><given-names>SR</given-names></name><name><surname>Browner</surname><given-names>WS</given-names></name><name><surname>Grady</surname><given-names>DG</given-names></name><name><surname>Newman</surname><given-names>TB</given-names></name></person-group><source xml:lang="pt">Delineando a pesquisa cl&#x000ed;nica: uma abordagem
epidemiol&#x000f3;gica</source><edition>3&#x000aa; ed</edition><publisher-loc>Porto Alegre</publisher-loc><publisher-name>Artmed</publisher-name><year>2008</year><size units="pages">384 p</size></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesiano</surname><given-names>ERAB</given-names></name><name><surname>Merch&#x000e1;n-Hamann</surname><given-names>E</given-names></name></person-group><article-title>Bloodstream infections among patients using central
venous catheters in intensive care units</article-title><source>Rev. Latino-Am. Enfermagem.</source><year>2007</year><volume>15</volume><issue>3</issue><fpage>453</fpage><lpage>459</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>KM</given-names></name><name><surname>Litton</surname><given-names>E</given-names></name></person-group><article-title>Use of chlorhexidine-impregnated dressing to prevent
vascular and epidural catheter colonization and infection: a
meta-analysis</article-title><source>J Antimicrob Chemother.</source><year>2006</year><volume>58</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">16757502</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timsit</surname><given-names>JF</given-names></name><name><surname>Schwebel</surname><given-names>C</given-names></name><name><surname>Bouadma</surname><given-names>L</given-names></name><name><surname>Geffroy</surname><given-names>A</given-names></name><name><surname>Garrouste-Orgeas</surname><given-names>M</given-names></name><name><surname>Pease</surname><given-names>S</given-names></name></person-group><article-title>Chlorhexidine-impregnated sponges and less frequent
dressing changes for prevention of catheter-related infections in critically ill
adults: a randomized controlled trial</article-title><source>JAMA.</source><year>2009</year><volume>301</volume><fpage>1231</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">19318651</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruschulte</surname><given-names>H</given-names></name><name><surname>Franke</surname><given-names>M</given-names></name><name><surname>Gastmeier</surname><given-names>P</given-names></name><name><surname>Zenz</surname><given-names>S</given-names></name><name><surname>Mahr</surname><given-names>KH</given-names></name><name><surname>Buchholz</surname><given-names>S</given-names></name></person-group><article-title>Prevention of central venous catheter related infections
with chlorhexidine gluconate impregnated wound dressings: a randomized controlled
trial</article-title><source>Ann Hematol.</source><year>2009</year><volume>88</volume><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">18679683</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques Netto</surname><given-names>S</given-names></name><name><surname>Echer</surname><given-names>IC</given-names></name><name><surname>Kuplich</surname><given-names>NM</given-names></name><name><surname>Kuchenbecker</surname><given-names>R</given-names></name><name><surname>Kessler</surname><given-names>F</given-names></name></person-group><article-title>Infec&#x000e7;&#x000e3;o de cateter vascular central em pacientes
adultos de um centro de terapia intensiva</article-title><source>Rev Ga&#x000fa;cha Enferm.</source><month>9</month><year>2009</year><volume>30</volume><issue>3</issue><fpage>429</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">20187423</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrolo</surname><given-names>E</given-names></name><name><surname>Danski</surname><given-names>MTR</given-names></name><name><surname>Mingorance</surname><given-names>P</given-names></name><name><surname>De Lazzari</surname><given-names>LSM</given-names></name><name><surname>Johann</surname><given-names>DA</given-names></name></person-group><article-title>Clinical controlled trial on central venous catheter
dressings</article-title><source>Acta Paul Enferm.</source><year>2011</year><volume>24</volume><issue>2</issue><fpage>278</fpage><lpage>283</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frasca</surname><given-names>D</given-names></name><name><surname>Dahyot-Fizelier</surname><given-names>C</given-names></name><name><surname>Mimoz</surname><given-names>O</given-names></name></person-group><article-title>Prevention of central venous catheter-related infection
in the intensive care unit</article-title><source>Critical Care.</source><year>2010</year><volume>14</volume><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">20236456</pub-id></element-citation></ref></ref-list></back></article>